Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Fomivirsen sodium
Fomivirsen · 2 trials · 2 indications
| Name | Type | Description |
|---|---|---|
| Fomivirsen sodium | DRUG | - |
| Ganciclovir | DRUG | - |
Inclusion Criteria Patients must have: * AIDS. * CMV retinitis that is not adequately controlled (previously diagnosed patients with smoldering CMV retinitis or those with active CMV retinitis borders on indirect ophthalmoscopy). * No more than one previous progression of CMV retinitis. Exclusion...
Fomivirsen is an investigational RNA therapy studied for the treatment of cytomegalovirus retinitis, a viral eye infection that occurs in patients with AIDS and other immunocompromised conditions. It was evaluated in Phase 2 clinical trials in patients with CMV of the eyes and HIV infection.
Fomivirsen is an antisense oligonucleotide, part of the -sen (ASO) target class. It is designed to bind to viral messenger RNA and block the production of proteins the cytomegalovirus needs to replicate. This antisense mechanism is intended to inhibit CMV replication in the eye.
Fomivirsen is developed by Ionis Pharmaceuticals, Inc., which trades on the Nasdaq under the ticker IONS. The company is the sponsor behind the clinical development program for the drug in cytomegalovirus retinitis.
Fomivirsen is in Phase 2 clinical development. It is an investigational drug and has not been established as approved for commercial use. Two Phase 2 trials have been completed, and no trials are currently active.
Fomivirsen has been studied in two completed Phase 2 trials. NCT00002356 evaluated the safety and effectiveness of ISIS 2922 in patients with AIDS who have cytomegalovirus of the eyes. NCT00002156 compared intravitreal ISIS 2922 plus ganciclovir versus ganciclovir alone in patients with cytomegalovirus retinitis, enrolling 194 participants.
Yes, fomivirsen sodium is another name for fomivirsen. The two names refer to the same antisense oligonucleotide drug developed by Ionis Pharmaceuticals for cytomegalovirus retinitis, so readers searching either term are looking at the same asset.